Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, treatment with VER-01, a full-spectrum cannabis extract, was evaluated over 12 weeks with extended follow-up lasting up to one year. The study used a rigorous placebo-controlled design before transitioning to open-label and withdrawal phases, providing a structured look at both short- and longer-term outcomes. Results from this trial add meaningful clinical evidence to the role of standardized cannabis-based medicines as potential alternatives to conventional pharmacologic treatments for chronic low back pain.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a significant clinical gap by evaluating a full-spectrum cannabis extract as an alternative to conventional analgesics for chronic low back pain, a condition affecting over 500 million people globally with inadequately treated patients due to opioid risks and NSAID limitations. The rigorous double-blind, placebo-controlled design with 820 participants provides the robust evidence needed to establish whether cannabis-derived therapeutics can offer meaningful efficacy and safety advantages for this high-burden condition. If positive, these results could expand the pharmacologic armamentarium for CLBP management and inform clinical guidelines regarding cannabinoid use in musculoskeletal pain disorders.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
🔍 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain addresses a genuine clinical need, given the limitations and risks associated with conventional analgesics and the prevalence of CLBP globally. The relatively large sample size and placebo-controlled design provide meaningful evidence; however, key details about primary endpoints, effect sizes, and whether benefits persisted into the open-label extension remain unclear from the abstract alone, making it difficult to assess clinical significance versus statistical significance. Important confounders such as concurrent physical therapy, baseline pain severity stratification, and the specific cannabinoid and terpene profile of VER-01 warrant scrutiny, as full-spectrum extracts vary considerably and may not be directly comparable across formulations. Additionally, the generalizability to diverse patient populations and real-world dosing scenarios requires careful consideration before integrating into routine practice. If this trial demonstrates clinically meaningful pain reduction with an acceptable safety profile, it could offer patients an evidence-based botanical alternative, particularly for those who have exhaust